SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
(NasdaqGM:YMAB), Acquisition to Include Naxitamab-gqgk DANYELZA(R) (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, […]